Pilania Rakesh Kumar, Bhattarai Dharmagat, Singh Surjit
Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.
World J Clin Pediatr. 2018 Feb 8;7(1):27-35. doi: 10.5409/wjcp.v7.i1.27.
Kawasaki disease (KD) is a common medium vessel systemic vasculitis that usually occurs in small children. It has a predilection for the coronary arteries, but other medium sized arteries can also be involved. The etiology of this disorder remains a mystery. Though typical presentation of KD is quite characteristic, it may also present as incomplete or atypical disease in which case the diagnosis can be very challenging. As both incomplete and atypical forms of KD can be associated with serious coronary artery complications, the pediatrician can ill afford to miss these diagnoses. The American Heart Association has enunciated consensus guidelines to facilitate the clinical diagnosis and treatment of this condition. However, there are still several issues that remain controversial. Intravenous immunoglobulin remains the cornerstone of management but several other treatment modalities, especially glucocorticoids, are increasingly finding favour. We review here some of the contemporary issues, and the controversies thereon, pertaining to management of KD.
川崎病(KD)是一种常见的累及中等大小血管的全身性血管炎,通常发生于小儿。它好发于冠状动脉,但其他中等大小动脉也可受累。这种疾病的病因仍是个谜。虽然川崎病的典型表现颇具特征性,但它也可能表现为不完全或非典型疾病,在这种情况下诊断可能极具挑战性。由于川崎病的不完全和非典型形式都可能伴有严重的冠状动脉并发症,儿科医生绝不能漏诊这些病例。美国心脏协会已阐明了共识指南,以促进对该病的临床诊断和治疗。然而,仍有几个问题存在争议。静脉注射免疫球蛋白仍然是治疗的基石,但其他几种治疗方式,尤其是糖皮质激素,越来越受到青睐。我们在此回顾一些与川崎病治疗相关的当代问题及其争议。